


Claims:

1. A compound in accord with formula I:



- 5 wherein:

R^1 and R^2 at each occurrence is independently selected from hydrogen, CN, CF_3 , OCF_3 , $OCHF_2$, halogen, C_{1-4} alkyl, C_{2-4} alkenyl, C_{2-4} alkynyl, R^a , R^b , SR^a , NR^aR^b , $CH_2NR^aR^b$, OR^c , or CH_2OR^c , where R^a , R^b , and R^c are independently at each occurrence selected from hydrogen, C_{1-6} alkyl, $C(O)R^d$, $C(O)NHR^d$, CO_2R^d , or R^a and R^b may together be

- 10 $(CH_2)_jG(CH_2)_k$ or $G(CH_2)_jG$ where G is oxygen, j is 1, 2, 3 or 4, k is 0, 1 or 2; R^d at each occurrence is independently selected from C_{1-6} alkyl;


R^3 is hydrogen or C_{1-4} alkyl;

R^6 is hydrogen, CN, C_{1-4} alkyl or C_{1-4} alkoxy;

R^7 is hydrogen or C_{1-4} alkyl, and

- 15 Ar is phenyl or phenyl substituted at one or two positions with moieties independently selected from R^4 or R^5 where R^4 and R^5 are at each occurrence independently selected from halogen, C_{1-4} alkoxy or halogenated C_{1-4} alkyl; in vivo-hydrolysable precursors thereof, and pharmaceutically-acceptable salts thereof.

- 20 2. A compound according to Claim 1, in accord with formula II,



wherein:

R^1 , R^2 , R^3 , R^4 , R^5 and R^7 are as defined in Claim 1,

in vivo-hydrolysable precursors thereof, and pharmaceutically-acceptable salts thereof.

3. A compound according to Claim 1, wherein:

Ar is selected from 4-chlorophenyl, 4-fluorophenyl, 4-methoxyphenyl, 3,4-
5 dichlorophenyl, 3,4-dimethoxyphenyl, or 4-trifluoromethylphenyl,
in vivo-hydrolysable precursors thereof, and pharmaceutically-acceptable salts thereof.

4. A compound according to Claim 1, wherein

R¹ is selected from hydrogen, methoxy or ethyl;
10 R² is selected from hydrogen or methoxy;
R³ is selected from hydrogen or methyl;
in vivo-hydrolysable precursors thereof, and pharmaceutically-acceptable salts thereof.

5. A pharmaceutically-acceptable salts of a compound according to Claim 1 made with
15 an inorganic or organic acid which affords a physiologically-acceptable anion.

6. A pharmaceutically-acceptable salts of a compound according to Claim 5, wherein
said inorganic or organic acid is selected from hydrochloric, hydrobromic, sulfuric,
phosphoric, methanesulfonic, sulfamic, para-toluenesulfonic, acetic, citric, lactic, tartaric,
20 malonic, fumaric, ethanesulfonic, benzenesulfonic, cyclohexylsulfamic, salicylic or quinic
acids.

7. A pharmaceutical composition comprising a compound according to Claim 1; an in
vivo-hydrolysable precursor or a pharmaceutically-acceptable salt thereof and a
25 pharmaceutically-acceptable carrier.

8. A method of treating a disease condition wherein antagonism of NK₁ receptors in
combination with SSRI activity is beneficial which method comprises administering to a
warm-blooded animal an effective amount of a compound according to Claim 1 or an in vivo-
30 hydrolysable precursor or a pharmaceutically-acceptable salt thereof.

- 9 The use of a compound according to Claim 1 or an in vivo-hydrolysable precursor or a pharmaceutically-acceptable salt thereof in the preparation of a medicament for use in a disease condition wherein antagonism of the NK₁ receptors and SSRI activity is beneficial.
- 5 10. A method for treating a disorder or condition selected from hypertension, depression in cancer patients, depression in Parkinson's patients, postmyocardial infarction depression, subsyndromal symptomatic depression, depression in infertile women, pediatric depression, major depression, single episode depression, recurrent depression, child abuse induced depression, post partum depression, generalized anxiety disorder, agoraphobia, social phobia, 10 simple phobias, posttraumatic stress syndrome, avoidant personality disorder, premature ejaculation, anorexia nervosa, bulimia nervosa, obesity, addictions to alcohol, cocaine, heroin, phenobarbital, nicotine or benzodiazepines; cluster headache, migraine, pain, Alzheimer's disease, obsessive-compulsive disorder, panic disorder, dementia, amnestic disorders, age-related cognitive decline, dementia in Parkinson's disease, neuroleptic-induced parkinsonism, 15 tardive dyskinesias, hyperprolactinaemia, vasospasm, cerebral vasculature vasospasm, cerebellar ataxia, gastrointestinal tract disorders, negative symptoms of schizophrenia, premenstrual syndrome, fibromyalgia syndrome, stress incontinence, Tourette's syndrome, trichotillomania, kleptomania, male impotence, attention deficit hyperactivity disorder, chronic paroxysmal hemicrania or headache associated with vascular disorders in a mammal, 20 wherein antagonism of the NK₁ receptors and SSRI activity is beneficial, comprising administering an effective amount of a compound according to Claim 1 or a pharmaceutically-acceptable salt thereof effective in treating such disorder or condition.
- 25 11. The method according to Claim 10 wherein said compound is administered in combination with a pharmaceutically-acceptable carrier.